These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 9123821)

  • 1. Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate.
    Charles PC; Brown KW; Davis NL; Hart MK; Johnston RE
    Virology; 1997 Feb; 228(2):153-60. PubMed ID: 9123821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus.
    Elvin SJ; Bennett AM; Phillpotts RJ
    J Med Virol; 2002 Jul; 67(3):384-93. PubMed ID: 12116032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
    Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
    Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of cytokine expression and regulation of host protection following infection with molecularly cloned Venezuelan equine encephalitis virus.
    Grieder FB; Davis BK; Zhou XD; Chen SJ; Finkelman FD; Gause WC
    Virology; 1997 Jul; 233(2):302-12. PubMed ID: 9217054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccinia virus recombinants encoding the truncated structural gene region of Venezuelan equine encephalitis virus (VEEV) give solid protection against peripheral challenge but only partial protection against airborne challenge with virulent VEEV.
    Phillpotts RJ; Lescott TL; Jacobs SC
    Acta Virol; 2000 Oct; 44(5):233-9. PubMed ID: 11252667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses.
    Fine DL; Roberts BA; Teehee ML; Terpening SJ; Kelly CL; Raetz JL; Baker DC; Powers AM; Bowen RA
    Vaccine; 2007 Feb; 25(10):1868-76. PubMed ID: 17240002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins.
    Grieder FB; Davis NL; Aronson JF; Charles PC; Sellon DC; Suzuki K; Johnston RE
    Virology; 1995 Feb; 206(2):994-1006. PubMed ID: 7856110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-site mutant and revertants arising in vivo define early steps in the pathogenesis of Venezuelan equine encephalitis virus.
    Aronson JF; Grieder FB; Davis NL; Charles PC; Knott T; Brown K; Johnston RE
    Virology; 2000 Apr; 270(1):111-23. PubMed ID: 10772984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus.
    Reed DS; Lind CM; Lackemeyer MG; Sullivan LJ; Pratt WD; Parker MD
    Vaccine; 2005 May; 23(24):3139-47. PubMed ID: 15837213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice.
    Hart MK; Pratt W; Panelo F; Tammariello R; Dertzbaugh M
    Vaccine; 1997 Mar; 15(4):363-9. PubMed ID: 9141206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus.
    Phillpotts RJ; O'brien L; Appleton RE; Carr S; Bennett A
    Vaccine; 2005 Feb; 23(13):1615-23. PubMed ID: 15694514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine.
    Greenway TE; Eldridge JH; Ludwig G; Staas JK; Smith JF; Gilley RM; Michalek SM
    Vaccine; 1998 Aug; 16(13):1314-23. PubMed ID: 9682396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In mice the efficiency of immunization with Venezuelan Equine Encephalomyelitis virus TC-83 is transiently increased by dehydroepiandrosterone.
    Negrette B; Bonilla E; Valero N; Giraldoth D; Medina-Leendertz S; Añez F
    Invest Clin; 2001 Dec; 42(4):235-40. PubMed ID: 11787268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses.
    Paessler S; Ni H; Petrakova O; Fayzulin RZ; Yun N; Anishchenko M; Weaver SC; Frolov I
    J Virol; 2006 Mar; 80(6):2784-96. PubMed ID: 16501087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate.
    Hart MK; Caswell-Stephan K; Bakken R; Tammariello R; Pratt W; Davis N; Johnston RE; Smith J; Steele K
    Vaccine; 2000 Jul; 18(26):3067-75. PubMed ID: 10825611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.
    Caley IJ; Betts MR; Irlbeck DM; Davis NL; Swanstrom R; Frelinger JA; Johnston RE
    J Virol; 1997 Apr; 71(4):3031-8. PubMed ID: 9060663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.
    Davis NL; Brown KW; Johnston RE
    J Virol; 1996 Jun; 70(6):3781-7. PubMed ID: 8648713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of homologous and heterologous antibody response in California horses vaccinated with attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83).
    Ferguson JA; Reeves WC; Milby MM; Hardy JL
    Am J Vet Res; 1978 Mar; 39(3):371-6. PubMed ID: 637386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.
    Greer CE; Zhou F; Goodsell A; Legg HS; Tang Z; zur Megede J; Uematsu Y; Polo JM; Vajdy M
    Scand J Immunol; 2007 Dec; 66(6):645-53. PubMed ID: 17944814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody studies in ponies vaccinated with Venezuelan equine encephalomyelitis (strain TC-83) and other alphavirus vaccines.
    Ferguson JA; Reeves WC; Hardy JL
    Am J Vet Res; 1977 Apr; 38(4):425-30. PubMed ID: 851275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.